Clinical Trial Update: Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating immunogenicity and safety of GSK's Herpes Zoster vaccine co-administered with Pneumovax 23 in adults 50+; study completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• GSK1437173A (Herpes Zoster vaccine) (GSK1437173A)
• Pneumovax 23 (Pneumococcal polysaccharide vaccine 23-valent)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Herpes Zoster, Herpes Zoster Vaccine | Phase 3 | Status: COMPLETED | Results posted: 2017-07-05